Evidence map›Paper›PMID 38338853›Full record

ReviewInternational journal of molecular sciences2024

Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights.

Andrea D'Amato, Silvia Prosperi, Paolo Severino, Vincenzo Myftari, Aurora Labbro Francia, Claudia Cestiè, Nicola Pierucci, Stefanie Marek-Iannucci, Marco Valerio Mariani, Rosanna Germanò and 7 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 30 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Observational
  5. Article
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Observational
  13. Review
  14. Article
  15. Review
  16. Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Andrea D'AmatoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Silvia ProsperiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Paolo SeverinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-6211-4482
Vincenzo MyftariDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Aurora Labbro FranciaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Claudia CestièDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Nicola PierucciDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-5985-4081
Stefanie Marek-IannucciDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-9621-3198
Marco Valerio MarianiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-9480-1209
Rosanna GermanòDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Francesca FanisioDivision of Cardiology, Policlinico Casilino, 00169 Rome, Italy.ORCID 0000-0002-1488-7015
Carlo LavalleDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Viviana MaestriniDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3225-8378
Roberto BadagliaccaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-7887-5961
Massimo ManconeDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-0881-7299
Francesco FedeleSan Raffaele Cassino, 03043 Cassino, Italy.
Carmine Dario VizzaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3540-4983
Sapienza University of Rome · ITPoliclinico Casilino · ITUniversità degli studi di Cassino e del Lazio Meridionale · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worsening heart failure (WHF) is a severe and dynamic condition characterized by significant clinical and hemodynamic deterioration. It is characterized by worsening HF signs, symptoms and biomarkers, despite the achievement of an optimized medical therapy. It remains a significant challenge in cardiology, as it evolves into advanced and end-stage HF. The hyperactivation of the neurohormonal, adrenergic and renin-angiotensin-aldosterone system are well known pathophysiological pathways involved in HF. Several drugs have been developed to inhibit the latter, resulting in an improvement in life expectancy. Nevertheless, patients are exposed to a residual risk of adverse events, and the exploration of new molecular pathways and therapeutic targets is required. This review explores the current landscape of WHF, highlighting the complexities and factors contributing to this critical condition. Most recent medical advances have introduced cutting-edge pharmacological agents, such as guanylate cyclase stimulators and myosin activators. Regarding device-based therapies, invasive pulmonary pressure measurement and cardiac contractility modulation have emerged as promising tools to increase the quality of life and reduce hospitalizations due to HF exacerbations. Recent innovations in terms of WHF management emphasize the need for a multifaceted and patient-centric approach to address the complex HF syndrome.

Indexed as

Heart FailureQuality of LifeHospitalizationHumansMyocardial ContractionStroke Volumecardiac contractility modulationlevosimendanomecamtiv mecarbilSGLT2ivericiguatworsening heart failure

Identifiers

PMID38338853
PMCPMC10855688
OpenAlexW4391317609

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.